Want to see JP:4593 full AI Analyst Report?

Healios KK (4593) Price & Analysis

8 Followers

4593 Stock Chart & Stats

¥370.00

¥3.00(1.60%)

At close: Jan 08 4:00 PM EST

¥370.00

¥3.00(1.60%)

Day’s Range― - ―

52-Week Range¥208.00 - ¥628.00

Previous CloseN/A

Volume811.70K

Average Volume (3M)1.89M

Market Cap

¥39.83B

Enterprise Value¥27.68K

Total Cash (Recent Filing)¥9.07B

Total Debt (Recent Filing)¥2.57B

Price to Earnings (P/E)59.1

Beta1.15

Next Earnings

Nov 18, 2026

EPS Estimate

-12.47

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)4.96

Shares Outstanding135,002,200

10 Day Avg. Volume2,150,970

30 Day Avg. Volume1,887,493

Financial Highlights & Ratios

PEG Ratio0.23

Price to Book (P/B)6.03

Price to Sales (P/S)283.63

P/FCF Ratio-8.85

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-30.72

Revenue Forecast (FY)¥589.80M

Bulls Say, Bears Say

Bulls Say

Improved Balance Sheet LeverageLower leverage and stronger equity provide more financial flexibility for ongoing clinical development. This relative balance-sheet improvement may help Healios fund its platform while reducing immediate dependence on additional borrowing.

Regenerative Medicine Platform FocusHealios is focused on regenerative medicine, an area with potential for differentiated therapies and platform reuse across indications. Its somatic-cell and iPSC capabilities could support multiple development programs over the medium term.

Milestone And Royalty-based Revenue PotentialThe partnership-led model can reduce the need to commercialize every therapy independently and create revenue inflection points when programs advance. Successful approvals could also provide recurring royalty or commercial income.

Bears Say

Persistent Operating LossesDeep operating losses and negative gross margin indicate that current activities are not covering their underlying costs. Without meaningful clinical, licensing, or commercial progress, profitability may remain structurally difficult to achieve.

Declining And Volatile RevenueFalling and volatile revenue makes operating planning difficult and suggests limited recurring income from collaborations or products. This weak visibility increases reliance on uncertain pipeline milestones and future partnering activity.

Severe Cash ConsumptionHealios continues to consume substantial cash rather than generate it, creating ongoing funding risk for clinical development and manufacturing capabilities. Persistent burn could erode the improved balance sheet and require new financing.

Healios KK News

Healios Flags Disclosure Limits in FY2026 Q2 Results Material

The latest update is out from Healios KK ( ($JP:4593) ). Healios K.K., a player in regenerative medicine,...

23d ago

4593

Healios’ MASTERS-2 Stroke Trial Update: What Investors Need to Know

Healios KK ($JP:4593) announced an update on their ongoing clinical study. The MultiStem Administration for Stroke Treatment and...

24d ago

4593

Healios Secures AMED Funding to Industrialize iPSC-Derived NK Cell Therapy

Healios KK ( ($JP:4593) ) has issued an update. Healios K.K., a clinical-stage regenerative medicine biotech in Japan,...

1M ago

4593

Healios Files Counterclaim in Payment Dispute with AND Medical

Healios KK ( ($JP:4593) ) has issued an update. Healios K.K. has filed a counterclaim in the Tokyo...

3M ago

4593

Healios Highlights Uncertainty Around FY2026 Q1 Disclosures and Outlook

The latest announcement is out from Healios KK ( ($JP:4593) ). Healios K.K. released materials related to its...

4M ago

4593

Healios Signs ¥144 Million Stem Cell Supernatant Supply Deal With JENECELL

An update from Healios KK ( ($JP:4593) ) is now available. Healios K.K. has agreed to supply human...

5M ago

4593

Healios Wins ¥7 Billion METI Subsidy to Build Regenerative Medicine CDMO Hub in Kobe

Healios KK ( ($JP:4593) ) has provided an update. Healios K.K., a leading Japanese regenerative medicine biotech, is...

5M ago

4593

Healios to Restructure Capital to Eliminate Losses Without Diluting Shareholders

An announcement from Healios KK ( ($JP:4593) ) is now available. Healios K.K. plans to reduce portions of...

7M ago

4593

Healios Proposes New Board Slate Ahead of March Shareholders Meeting

Healios KK ( ($JP:4593) ) just unveiled an update. Healios K.K. has nominated five candidates for its Board...

7M ago

4593

Healios Issues FY2025 Results With Strong Caution on Forward-Looking Data

Healios KK ( ($JP:4593) ) has provided an update. Healios K.K. released its FY2025 financial results materials primarily...

7M ago

4593

4593 FAQ

What was Healios KK’s price range in the past 12 months?

Healios KK lowest stock price was ¥208.00 and its highest was ¥628.00 in the past 12 months.

What is Healios KK’s market cap?

Healios KK’s market cap is ¥39.83B.

When is Healios KK’s upcoming earnings report date?

Healios KK’s upcoming earnings report date is Nov 18, 2026 which is in 75 days.

How were Healios KK’s earnings last quarter?

Healios KK released its earnings results on Aug 12, 2026. The company reported ¥10.13 earnings per share for the quarter, beating the consensus estimate of -¥2.429 by ¥12.559.

Is Healios KK overvalued?

According to Wall Street analysts Healios KK’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Healios KK pay dividends?

Healios KK does not currently pay dividends.

What is Healios KK’s EPS estimate?

Healios KK’s EPS estimate is -12.47.

How many shares outstanding does Healios KK have?

Healios KK has 135,002,200 shares outstanding.

What happened to Healios KK’s price movement after its last earnings report?

Healios KK reported an EPS of ¥10.13 in its last earnings report, beating expectations of -¥2.429. Following the earnings report the stock price went down -1.55%.

Which hedge fund is a major shareholder of Healios KK?

Currently, no hedge funds are holding shares in JP:4593

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Healios KK

Healios K.K., a Tokyo-based biopharmaceutical firm established in 2011, specializes in the discovery, development, manufacturing, and commercialization of advanced cell and regenerative medical therapies. The company operates across key markets including Japan, Europe, and the United States. Its robust pipeline features several cellular and tissue-based products, such as HLCR011 and HLCR012, which are induced pluripotent stem cell (iPSC)-derived regenerative medicines aimed at treating age-related macular degeneration. Another iPSC-based therapy, HLCL041, is being developed for metabolic liver disease. Furthermore, Healios is progressing HLCM051, a regenerative treatment designed for ischemic stroke and acute respiratory distress syndrome, alongside HLCN061 for solid tumor indications. The company also maintains a joint research partnership with Hyogo Medical University, focusing on eNK cell-based cancer immunotherapies to combat mesothelioma. Healios K.K. adopted its current name in September 2013, having previously operated under the name Retina Institute Japan, K.K.